Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, García-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O, Goschzik T, Pietsch T, Sill M, Pfister SM, Rutkowski S, Richardson S, Hill RM, Williamson D, Bailey S, Schwalbe EC, Clifford SC, Hicks D

Open source

DOI: 10.1007/s00401-023-02566-0
Published: 2023 May
Container: Acta neuropathologica
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00401-023-02566-0,
  title = {Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.},
  author = {Goddard J and Castle J and Southworth E and Fletcher A and Crosier S and Martin-Guerrero I and García-Ariza M and Navajas A and Masliah-Planchon J and Bourdeaut F and Dufour C and Ayrault O and Goschzik T and Pietsch T and Sill M and Pfister SM and Rutkowski S and Richardson S and Hill RM and Williamson D and Bailey S and Schwalbe EC and Clifford SC and Hicks D},
  year = {2023},
  journal = {Acta neuropathologica},
  doi = {10.1007/s00401-023-02566-0},
  url = {https://doi.org/10.1007/s00401-023-02566-0}
}

RIS

TY  - JOUR
TI  - Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
AU  - Goddard J
AU  - Castle J
AU  - Southworth E
AU  - Fletcher A
AU  - Crosier S
AU  - Martin-Guerrero I
AU  - García-Ariza M
AU  - Navajas A
AU  - Masliah-Planchon J
AU  - Bourdeaut F
AU  - Dufour C
AU  - Ayrault O
AU  - Goschzik T
AU  - Pietsch T
AU  - Sill M
AU  - Pfister SM
AU  - Rutkowski S
AU  - Richardson S
AU  - Hill RM
AU  - Williamson D
AU  - Bailey S
AU  - Schwalbe EC
AU  - Clifford SC
AU  - Hicks D
PY  - 2023
JO  - Acta neuropathologica
DO  - 10.1007/s00401-023-02566-0
UR  - https://doi.org/10.1007/s00401-023-02566-0
ER  -

APA

J, G., J, C., E, S., A, F., S, C., I, M., M, G., A, N., J, M., F, B., C, D., O, A., T, G., T, P., M, S., SM, P., S, R., S, R., RM, H., D, W., S, B., EC, S., SC, C., & D, H. (2023). Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.. Acta neuropathologica. https://doi.org/10.1007/s00401-023-02566-0

Source records

pubmed · retrieved 2026-09-25T19:09:37.863Z